High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties
MGMT overexpression identifies a previously undescribed subset of CRCs with distinct biological and clinical properties including reduced mutagenesis, adaptive immune evasion, predominantly pMMR phenotype and aggressive clinical course. Direct, quantitative assessment of MGMT protein expression using spatially resolved analysis is more reliable than inference of MGMT expression by promoter methylation status in CRC.
Authors
- Hongyu Zhao (ORCID: https://orcid.org/0000-0003-3213-9923)
- Barani Kumar Rajendran (ORCID: https://orcid.org/0000-0001-9675-7718)
- Yong Kong (ORCID: https://orcid.org/0000-0002-2881-5274)
- Joanna Gibson (ORCID: https://orcid.org/0000-0003-0406-4872)
- Shruti Desai (ORCID: https://orcid.org/0000-0002-5234-5890)
- Kurt A. Schalper (ORCID: https://orcid.org/0000-0001-5692-4833)
- Janie Y. Zhang (ORCID: https://orcid.org/0000-0002-0459-2635)
- Michael Cecchini (ORCID: https://orcid.org/0000-0003-3504-0128)
- Patricia LoRusso (ORCID: https://orcid.org/0000-0001-7144-036X)
Institutions
- Yale Cancer Center (US)
- Yale University (US)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/jitc-2025-011653
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Yale University
- Yale Cancer Center
- National Institutes of Health
- Stand Up To Cancer
- National Cancer Institute